Conference Coverage

AHA: Empagliflozin for T2D reduces heart failure endpoints

Publish date: November 25, 2015

 

AT THE AHA SCIENTIFIC SESSIONS

References

Dr. Inzucchi disclosed ties with Boehringer Ingelheim, Merck, Janssen, Novo Nordisk, Sanofi/Regeron, Intarcia, Lexicon, Paxel, Takeda, and Eli Lilly. He acknowledged CME funding to Yale University from Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Abbot, Merck Sharp & Dohme, and Sanofi.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

Survivors of childhood cancers at increased risk for autoimmune diseases
MDedge Endocrinology
VIDEO: Study shows how to stand up to the ‘sitting disease’
MDedge Endocrinology
Short-term adverse events modest after bariatric surgery in slimmer diabetics
MDedge Endocrinology
Equation predicts blindness, amputation risk in diabetes
MDedge Endocrinology
Artificial pancreas improved glycemia after islet cell transplant
MDedge Endocrinology
U.S. hospitalization rates overestimated for some causes
MDedge Endocrinology
Breastfeeding cuts risk of progression from GDM to type 2 diabetes
MDedge Endocrinology
Unsupervised, at-home closed-loop insulin delivery system
MDedge Endocrinology
AHA: Broadening evidence for CABG over PCI in diabetics
MDedge Endocrinology
Blood pressure above 140/80 worsens proteinuric diabetic kidney disease
MDedge Endocrinology

Related Articles